IM Cannabis Regains Compliance with Nasdaq Listing Requirements

Key Facts

In a move that strengthens its corporate standing and mitigates delisting risks, IM Cannabis Corp. announced it has officially regained compliance with Nasdaq's minimum bid price requirements. According to reports, the company received formal written notice from Nasdaq confirming it met the standards of Listing Rule 5550(a)(2), which mandates a minimum bid price of $4.14. This determination followed the company's ordinary shares maintaining a closing bid price of at least $4.14 for 18 consecutive business days between August 27 and September 22, 2026.

This regulatory milestone arrives amid strategic shifts, as the company expects to retain its Israeli medical cannabis operations while divesting its German business. Per market data, IMCC shares closed at $4.14 on September 22, 2026, trading within a range of $3.56 to $5.7 during that session. This price action represents a significant buffer above the Nasdaq minimum, effectively closing the deficiency matter that had previously shadowed the stock's listing status.

Looking ahead, investors are focused on the completion of pending transactions intended to streamline the company's platform. As of the close on September 22, 2026, IMCC stood at $4.14, maintaining a solid position relative to listing requirements. With no major sector-specific catalysts in the immediate economic calendar, the primary focus remains on the execution of the German asset sale and the optimization of the Israeli medical cannabis ecosystem.